Mandate

Vinge has advised Stendörren in connection with a bond issue of up to SEK 1,000 million

August 14, 2017

Vinge has advised Stendörren Fastigheter AB (publ) (“Stendörren”) in connection with a bond issue of up to SEK 1,000 million senior unsecured floating rate bonds.

The bonds have a tenor of three years and a floating interest rate of three-months Stibor plus 4 per cent. ABG Sundal Collier AB and Swedbank have acted as financial advisors to Stendörren. Swedbank also acted as Issuing Agent.

The proceeds from the initial bond issue will primarily be used for refinancing of Stendörren’s outstanding SEK 750 million bonds, which will be made through a repurchase offer. The proceeds from the bond issue will also be used for acquisitions, investments and general corporate purposes. 

In accordance with the terms and conditions, the bonds are intended to be listed and admitted to trading on the corporate bond list at Nasdaq Stockholm shortly. As a result, the Company has prepared a prospectus which today has been approved by and registered with the Swedish Financial Supervisory Authority.

Vinges team consisted of Louise Brorsson Salomon, David Andersson, Sabina Börjesson, Josefine Larsson, André Isacson, Lionardo Ojeda and William Kåge

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025